ERCC1 and non-small cell lung carcinoma: A potential effect of ERCC1 rs3212986 polymorphism on the overall survival of NSCLC patients was proposed by our data, which suggested that the patients carrying rs3212986 A allele were associated with a poorer response to platinum‐based chemotherapy and a shorter survival time in contrast to those carrying C allele, consistently with the previous reports.35, 36